471 related articles for article (PubMed ID: 29905759)
1. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Zhang J; Lin Y; Sun XJ; Wang BY; Wang ZH; Luo JF; Wang LP; Zhang S; Cao J; Tao ZH; Wu J; Shao ZM; Yang WT; Hu XC
Ann Oncol; 2018 Aug; 29(8):1741-1747. PubMed ID: 29905759
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
Zhang J; Wang Z; Hu X; Wang B; Wang L; Yang W; Liu Y; Liu G; Di G; Hu Z; Wu J; Shao Z
Int J Cancer; 2015 Jan; 136(1):204-11. PubMed ID: 24824628
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer.
Li Y; Zhao Y; Gong C; Xie Y; Hu X; Zhang J; Wang L; Zhang S; Cao J; Tao Z; Wang B
Sci Rep; 2019 Mar; 9(1):3563. PubMed ID: 30837503
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
[TBL] [Abstract][Full Text] [Related]
5. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
6. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Yardley DA; Coleman R; Conte P; Cortes J; Brufsky A; Shtivelband M; Young R; Bengala C; Ali H; Eakel J; Schneeweiss A; de la Cruz-Merino L; Wilks S; O'Shaughnessy J; Glück S; Li H; Miller J; Barton D; Harbeck N;
Ann Oncol; 2018 Aug; 29(8):1763-1770. PubMed ID: 29878040
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
Wang B; Sun T; Zhao Y; Wang S; Zhang J; Wang Z; Teng YE; Cai L; Yan M; Wang X; Jiang Z; Pan Y; Luo J; Shao Z; Wu J; Guo X; Hu X
Nat Commun; 2022 Jul; 13(1):4025. PubMed ID: 35821019
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Rui M; Shi F; Shang Y; Meng R; Li H
Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study.
Zhang J; Pan Y; Shi Q; Zhang G; Jiang L; Dong X; Gu K; Wang H; Zhang X; Yang N; Li Y; Xiong J; Yi T; Peng M; Song Y; Fan Y; Cui J; Chen G; Tan W; Zang A; Guo Q; Zhao G; Wang Z; He J; Yao W; Wu X; Chen K; Hu X; Hu C; Yue L; Jiang D; Wang G; Liu J; Yu G; Li J; Bai J; Xie W; Zhao W; Wu L; Zhou C
Cancer Commun (Lond); 2022 Jan; 42(1):3-16. PubMed ID: 34699693
[TBL] [Abstract][Full Text] [Related]
10. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
O'Shaughnessy J; Schwartzberg L; Danso MA; Miller KD; Rugo HS; Neubauer M; Robert N; Hellerstedt B; Saleh M; Richards P; Specht JM; Yardley DA; Carlson RW; Finn RS; Charpentier E; Garcia-Ribas I; Winer EP
J Clin Oncol; 2014 Dec; 32(34):3840-7. PubMed ID: 25349301
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
13. Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
Kim JY; Lee E; Park K; Im SA; Sohn J; Lee KS; Chae YS; Kim JH; Kim TY; Jung KH; Park YH;
Breast Cancer Res Treat; 2019 Nov; 178(2):367-377. PubMed ID: 31407230
[TBL] [Abstract][Full Text] [Related]
14. Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Chen Y; Guan Y; Wang J; Ma F; Luo Y; Chen S; Zhang P; Li Q; Cai R; Li Q; Mo H; Lan B; Chen X; Zhao W; Xu B; Fan Y
Int J Cancer; 2020 Dec; 147(12):3490-3499. PubMed ID: 32588429
[TBL] [Abstract][Full Text] [Related]
15. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
[TBL] [Abstract][Full Text] [Related]
19. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.
Wang J; Zheng R; Wang Z; Yang Y; Wang M; Zou W
Med Sci Monit; 2017 Sep; 23():4657-4664. PubMed ID: 28957036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
